The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study

Table 4 Mixed model repeated measure linear regression showing the association between NT-proBNP (dependent variable) and markers of disease activity and treatment

	Adjusted linear regression (CI)		Multivariate linear regression (CI)
	β coefficients (CI)	P value	β coefficients (CI)	P value
Age	1.03 (1.02–1.03)	< 0.001	1.02 (1.01–1.02)	< 0.001
Male gender	0.81 (0.64–1.01)	0.06	0.12 (0.05–0.26)	< 0.001
C-reactive protein^a	1.01 (1.01–1.02)	< 0.001	1.01 (1.01–1.02)	< 0.001
HAQ^a	1.12 (1.00–1.27)	0.06
Prednisolone^{a, b}	1.20 (1.03–1.41)	0.02
NSAID^{a, b}	0.90 (0.79–1.04)	0.14
DMARD^{a, b}	0.95 (0.83–1.09)	0.49
Sharp score^a	1.01 (1.00–1.01)	0.001
Ritchie score^a	1.01 (1.00–1.02)	0.01
Time	1.04 (1.03–1.06)	< 0.001	1.03 (1.02–1.05)	< 0.001
Time × male gender			1.04 (1.01–1.07)	0.01
Age × male gender			1.03 (1.02–1.05)	0.01

^aAge- and gender-adjusted; ^bdichotomized variable. CI, confidence interval; DMARD, disease-modifying anti-rheumatic drug; HAQ, Stanford Health Assessment Questionnaire; NSAID, non-steroidal anti-inflammatory drug; NT-proBNP, N-terminal pro-brain natriuretic peptide; Ritchie score, Ritchie articular index; Sharp score, van der Heijde modified Sharp criteria.

ISSN: 1478-6362